Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 10,125 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $26.07, for a total value of $263,958.75. Following the completion of the sale, the director directly owned 62,291 shares of the company’s stock, valued at $1,623,926.37. This represents a 13.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The shares were sold at an average price of $27.25, for a total value of $301,058.00.
• On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The shares were sold at an average price of $26.23, for a total value of $1,633,892.93.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total value of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Trading Up 6.6%

IMNM traded up $1.74 during trading on Wednesday, hitting $27.99. The stock had a trading volume of 1,561,300 shares, compared to its average volume of 1,383,354. The firm has a market cap of $3.17 billion, a PE ratio of -11.76 and a beta of 2.07. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $28.04. The company has a 50 day simple moving average of $21.73 and a 200-day simple moving average of $22.18.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, sell-side analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunome

Several institutional investors and hedge funds have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. raised its stake in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Immunome during the 2nd quarter valued at about $186,588,000. Vanguard Group Inc. boosted its position in shares of Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after acquiring an additional 1,144,788 shares in the last quarter. Primecap Management Co. CA increased its stake in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after acquiring an additional 1,667,432 shares during the period. Finally, State Street Corp increased its stake in Immunome by 37.9% in the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after acquiring an additional 1,064,027 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome News Summary

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
• Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
• Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release

Wall Street Analyst Weigh In

A number of brokerages have weighed in on IMNM. Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners dropped their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Truist Financial increased their target price on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.64.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.